JP2009528828A - 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 - Google Patents

消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 Download PDF

Info

Publication number
JP2009528828A
JP2009528828A JP2008557594A JP2008557594A JP2009528828A JP 2009528828 A JP2009528828 A JP 2009528828A JP 2008557594 A JP2008557594 A JP 2008557594A JP 2008557594 A JP2008557594 A JP 2008557594A JP 2009528828 A JP2009528828 A JP 2009528828A
Authority
JP
Japan
Prior art keywords
antibody
rsv
less
protein
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008557594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528828A5 (enExample
Inventor
ヨハン・ラント
ルシーラ・ステイナー
クラウス・ケーフェーズ
ラース・エス・ニールセン
ヘンリエッテ・シェーニング・ニールセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2009528828A publication Critical patent/JP2009528828A/ja
Publication of JP2009528828A5 publication Critical patent/JP2009528828A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008557594A 2006-03-06 2007-03-06 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 Withdrawn JP2009528828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600324 2006-03-06
US87471606P 2006-12-14 2006-12-14
PCT/DK2007/000113 WO2007101441A1 (en) 2006-03-06 2007-03-06 Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Publications (2)

Publication Number Publication Date
JP2009528828A true JP2009528828A (ja) 2009-08-13
JP2009528828A5 JP2009528828A5 (enExample) 2011-04-28

Family

ID=38230163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557594A Withdrawn JP2009528828A (ja) 2006-03-06 2007-03-06 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体

Country Status (12)

Country Link
US (1) US20100040606A1 (enExample)
EP (1) EP2004686A1 (enExample)
JP (1) JP2009528828A (enExample)
KR (1) KR20080113223A (enExample)
CN (1) CN101395182A (enExample)
AU (1) AU2007222798A1 (enExample)
BR (1) BRPI0708636A2 (enExample)
CA (1) CA2638833A1 (enExample)
IL (1) IL193386A0 (enExample)
MX (1) MX2008011280A (enExample)
WO (1) WO2007101441A1 (enExample)
ZA (1) ZA200806362B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539357A (ja) * 2010-07-09 2013-10-24 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
JP2016512554A (ja) * 2013-03-14 2016-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
RU2426795C2 (ru) 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
PL2132229T3 (pl) 2007-03-01 2016-12-30 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka
MX2009008908A (es) 2007-03-01 2009-08-28 Symphogen As Metodo para clonacion de anticuerpos analogos.
CN101679513A (zh) * 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
NZ581316A (en) 2007-05-25 2012-02-24 Symphogen As Method for manufacturing a recombinant polyclonal protein
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
CN101821289A (zh) * 2007-09-07 2010-09-01 西福根有限公司 重组制造抗rsv抗体的方法
WO2009042589A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
NZ585589A (en) * 2007-10-25 2012-07-27 Trellis Bioscience Inc Anti-rsv g protein antibodies
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
AU2009301505A1 (en) * 2008-10-06 2010-04-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB2483810B (en) 2008-11-07 2012-09-05 Sequenta Inc Methods for correlating clonotypes with diseases in a population
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
PT2387627E (pt) 2009-01-15 2016-06-03 Adaptive Biotechnologies Corp Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais
JP2012531202A (ja) 2009-06-25 2012-12-10 フレッド ハチンソン キャンサー リサーチ センター 適応免疫を測定する方法
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
JP2013507603A (ja) 2009-10-09 2013-03-04 シムフォゲン・アクティーゼルスカブ 署名ペプチドおよび質量分析による混合物中の個々の組換えタンパク質の多重定量化
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
EP2625295B1 (en) * 2010-10-08 2019-03-13 President and Fellows of Harvard College High-throughput immune sequencing
CA2824389A1 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
AU2012347460B2 (en) 2011-12-09 2017-05-25 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
JP6302847B2 (ja) 2012-03-05 2018-03-28 アダプティヴ バイオテクノロジーズ コーポレーション 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定
ES2711156T3 (es) 2012-05-08 2019-04-30 Adaptive Biotechnologies Corp Método para medir y calibrar el sesgo de amplificación en reacciones de PCR multiplexadas
PT2887959T (pt) * 2012-08-23 2019-02-01 Seattle Genetics Inc Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7
EP2904111B1 (en) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
CA2890427C (en) 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
US10119134B2 (en) 2013-03-15 2018-11-06 Abvitro Llc Single cell bar-coding for antibody discovery
CN103196731A (zh) * 2013-04-18 2013-07-10 王刚平 用于鉴别乳腺肌上皮病变的多重染色试剂及其检测方法
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20170292149A1 (en) 2014-03-05 2017-10-12 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
ES2777529T3 (es) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
SG10201911069WA (en) 2014-09-15 2020-01-30 Abvitro Llc High-throughput nucleotide library sequencing
NZ729808A (en) 2014-09-30 2022-02-25 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
US11725044B2 (en) 2014-10-15 2023-08-15 Xenothera Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
CA2968543C (en) 2014-11-25 2024-04-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
WO2018052789A1 (en) * 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3538558A4 (en) 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES USING CHIMERIC PROTEIN
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
JP2021521896A (ja) 2018-04-27 2021-08-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト由来の抗（ポリｇａ）ジペプチドリピート（ｄｐｒ）抗体
US20220025019A1 (en) * 2018-11-30 2022-01-27 Csl Behring Ag Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
AU2020264492A1 (en) * 2019-04-30 2021-10-14 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
JP2024508222A (ja) * 2021-01-29 2024-02-26 アムジエン・インコーポレーテツド 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法
CN113249333B (zh) * 2021-03-16 2023-06-02 贵州省人民医院 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767610A (en) * 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
WO1992001473A1 (en) * 1990-07-19 1992-02-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5344640A (en) * 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5762905A (en) * 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
CA2198279A1 (en) * 1994-08-25 1996-02-29 Johannes Petrus Maria Langedijk Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
US5922344A (en) * 1995-02-10 1999-07-13 Abbott Laboratories Product for prevention of respiratory virus infection and method of use
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
EP2341074A1 (en) * 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
ATE412666T1 (de) * 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
CA2512647C (en) * 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
US6821450B2 (en) * 2003-01-21 2004-11-23 Hewlett-Packard Development Company, L.P. Substrate and method of forming substrate for fluid ejection device
JP4783726B2 (ja) * 2003-03-28 2011-09-28 メディミューン，エルエルシー 呼吸器合胞体ウイルスサブグループｂ株９３２０に関連する組成物および方法
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1793850A4 (en) * 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
CN101679513A (zh) * 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013539357A (ja) * 2010-07-09 2013-10-24 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
JP2015198658A (ja) * 2010-07-09 2015-11-12 クルセル ホランド ベー ヴェー 抗呼吸器多核体ウイルス（抗ｒｓｖ）抗体、その抗原結合断片、それらの使用、多価抗体、製薬上組成物、ｒｓｖ感染を検出する方法、および核酸
JP2016512554A (ja) * 2013-03-14 2016-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 呼吸器合胞体ウイルスｆタンパク質に対するヒト抗体及びその使用方法

Also Published As

Publication number Publication date
CA2638833A1 (en) 2007-09-13
US20100040606A1 (en) 2010-02-18
AU2007222798A1 (en) 2007-09-13
BRPI0708636A2 (pt) 2011-06-07
IL193386A0 (en) 2011-08-01
ZA200806362B (en) 2009-05-27
EP2004686A1 (en) 2008-12-24
KR20080113223A (ko) 2008-12-29
WO2007101441A1 (en) 2007-09-13
MX2008011280A (es) 2008-09-12
CN101395182A (zh) 2009-03-25

Similar Documents

Publication Publication Date Title
US7879329B2 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
JP2009528828A (ja) 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体
TWI627964B (zh) 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
US10196438B2 (en) Human antibodies binding to RSV G protein
CA2703667C (en) Anti-rsv g protein antibodies
CA2908921C (en) Human antibodies binding to rsv g protein
US11370829B2 (en) Antibodies that potently neutralize RSV and uses thereof
CA2223033A1 (en) High affinity human monoclonal antibodies specific for rsv f-protein
CN104350069B (zh) 中和rsv、mpv和pvm的抗体和其应用
US20240262894A1 (en) Antibody against respiratory syncytial virus and use thereof
TW200837079A (en) Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100305

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120222